Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Varun Nandakumar

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2026
Bispecific Antibody Therapy With Elranatamab for Refractory Waldenström Macroglobulinemia: A Case ReportVarun Nandakumar, Amandeep Godara, Felix Mensah
Bladder Cancer (Amsterdam, Netherlands)|April 1, 2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumabGeorges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, et al.
JAMA Network Open|June 29, 2026
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate CancerGabriel Hooper, Yeonjung Jo, Varun Nandakumar, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2026
Bispecific Antibody Therapy With Elranatamab for Refractory Waldenström Macroglobulinemia: A Case ReportVarun Nandakumar, Amandeep Godara, Felix Mensah
Bladder Cancer (Amsterdam, Netherlands)|April 1, 2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumabGeorges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, et al.
JAMA Network Open|June 29, 2026
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate CancerGabriel Hooper, Yeonjung Jo, Varun Nandakumar, et al.
Pageof 1